Product Information
RETACRIT 2,000 UNIT/ML VIAL is a brand biologic product labeled by Pfizer Inc., priced at $22.5227 per ML under NDC 00069130510. Its NADAC has been published 68 times since Jun 18, 2025.
Strength
2000 [iU]/mL
Manufacturer
Pfizer Inc.NDC
00069130510
Classification
Brand Biologic
Dosage Form
INJECTION, SOLUTION
Route
INTRAVENOUS; SUBCUTANEOUS
Effective Date
7/1/2026
Active Ingredients
EPOETINApproval Type
Biologic (BLA)
FDA Application
BLA125545On Market Since
6/18/2018
Pharmacological Classes
Price Statistics
The NADAC for RETACRIT 2,000 UNIT/ML VIAL has been published 68 times since Jun 18, 2025, and over the history we have for it it has risen 5.2%. The table below summarizes its recorded NADAC range and movement.
| Current price | $22.5227 per ML |
|---|---|
| All-time high | $22.5227 (Sep 30, 2026) |
| All-time low | $21.4035 (Aug 20, 2025) |
| 52-week high | $22.5227 |
| 52-week low | $21.4035 |
| Median price | $21.9820 |
| Average price | $21.8578 |
| Largest weekly change | +2.5% (Dec 31, 2025) |
| Weeks tracked | 68 |
| Tracking since | Jun 18, 2025 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the epoetin alfa-epbx market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Pfizer Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
epoetin alfa-epbx market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Erythropoiesis-stimulating Agent class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of RETACRIT 2,000 UNIT/ML VIAL?
The current National Average Drug Acquisition Cost (NADAC) for RETACRIT 2,000 UNIT/ML VIAL, manufactured by Pfizer Inc., is $22.5227 per ML (NDC 00069130510), effective Sep 30, 2026.
How has the price of RETACRIT 2,000 UNIT/ML VIAL changed over time?
Over the history we have for it, the NADAC for RETACRIT 2,000 UNIT/ML VIAL has risen 5.2%. It has been tracked across 68 weekly CMS publications since Jun 18, 2025.
What are the highest and lowest recorded NADAC prices for RETACRIT 2,000 UNIT/ML VIAL?
Since Jun 18, 2025, the NADAC for RETACRIT 2,000 UNIT/ML VIAL has ranged from a low of $21.4035 (Aug 20, 2025) to a high of $22.5227 (Sep 30, 2026), with a median of $21.9820 per ML.
Are there cheaper alternatives to RETACRIT 2,000 UNIT/ML VIAL?
No other NADAC-published product currently shares the active ingredient and strength of RETACRIT 2,000 UNIT/ML VIAL in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures RETACRIT 2,000 UNIT/ML VIAL?
RETACRIT 2,000 UNIT/ML VIAL (NDC 00069130510) is labeled by Pfizer Inc., and CMS classifies it as a brand biologic product.